Adaptimmune isn’t the only one hiring, others are hiring too! Check it out! (Isn’t it tempting?)
A biotech firm is set to more than double in size by the end of the year after seeing its key cancer therapy adopted by an industry giant. Adaptimmune will see its Milton Park-based workforce increase from 30 currently to 70 in the next six months thanks to GlaxoSmithKline signed a deal to develop and commercialise its T-cell receptor (TCR) engineering technology which focuses on encouraging the body’s immune system to battle cancer. TCR is in trials for multiple cancers in the United States with European trials set to start shortly.
Don’t forget, hundreds of biopharma companies are hiring! (We know you can’t resist.)
